TauRx Therapeutics Ltd (sponsor), 2018-03-14: Registry record for the mild-AD phase 3 trial (n=800, 200 mg/day vs a nominally inactive 8 mg/day 'placebo'): completed May 2016, no results posted on ClinicalTrials.gov as of 2026-11-21.
The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
TauRx Therapeutics Ltd (sponsor), 2018-03-14: Registry record for the mild-AD phase 3 trial (n=800, 200 mg/day vs a nominally inactive 8 mg/day 'placebo'): completed May 2016, no results posted on ClinicalTrials.gov as of 2026-11-21. Record fields from ClinicalTrials.gov API v2: Phase 3, randomised, double-blind, placebo-controlled, 78-week co-primary ADAS-cog11 and ADCS-ADL23; actual enrolment 800; start 2012-10, primary completion 2016-05; overall status COMPLETED; hasResults=false (no results section). The 'placebo' arm received 8 mg/day of active drug – recorded verbatim. The 18-month results were presented at CTAD December 2016 (see MTC-084) and re-analysed post hoc in MTC-097. hosting=LINK because the ClinicalTrials.gov study record is HTML-only (no PDF); copyright remains US Federal Public Domain. The record text was read from https://clinicaltrials.gov/api/v2/studies/NCT01689233 and the study page is JavaScript-rendered. Also filed as MTP-26, MTK-19 (claims C3, C4, F1).
